Sort by

Send to

Choose Destination

Search results

Items: 4


Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators..

N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.


Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis.

Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, Cederbrant KE, Gibson NJ, Armstrong M, Lagerström-Fermér ME, Dellsén A, Brown EM, Thornton M, Dukes C, Jenkins SC, Firth MA, Harrod GO, Pinel TH, Billing-Clason SM, Cardon LR, March RE.

Pharmacogenomics J. 2008 Jun;8(3):186-95. Epub 2007 May 15.


Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.

Wåhlander K, Eriksson H, Lundström T, Billing Clason S, Wall U, Nyström P, Wessman P, Schulman S; THRIVE III Investigators..

Br J Haematol. 2006 Apr;133(1):68-77.


Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.

Schulman S, Lundström T, Wålander K, Billing Clason S, Eriksson H.

Thromb Haemost. 2005 Oct;94(4):820-4.


Supplemental Content

Loading ...
Support Center